NewAmsterdam Pharma Co N.V. (NAMS) stock
NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW
$19.39−0.07 (-0.36%)
Close on Nov 17, 2026Market cap $2.32BP/E –Yield –
NewAmsterdam Pharma ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
NewAmsterdam Pharma's ebitda for the twelve months ending Jun 30, 2026 was -$244.07M. For fiscal 2025 it was -$225.46M. The highest annual figure on record is -$3.55M in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$225.46M | – |
| FY2024 | Dec 31, 2024 | -$176.18M | – |
| FY2023 | Dec 31, 2023 | -$182.92M | – |
| FY2022 | Dec 31, 2022 | -$3.55M | – |
| FY2021 | Dec 31, 2021 | -$34.97M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$64.78M | – |
| Q1 FY2026 | Mar 31, 2026 | -$58.36M | – |
| Q4 FY2025 | Dec 31, 2025 | -$65.92M | – |
| Q3 FY2025 | Sep 30, 2025 | -$55.02M | – |
| Q2 FY2025 | Jun 30, 2025 | -$35.53M | – |
| Q1 FY2025 | Mar 31, 2025 | -$68.87M | – |
| Q4 FY2024 | Dec 31, 2024 | -$43.18M | – |
| Q3 FY2024 | Sep 30, 2024 | -$24.91M | – |
| Q2 FY2024 | Jun 30, 2024 | -$52.51M | – |
| Q1 FY2024 | Mar 31, 2024 | -$55.47M | – |
| Q4 FY2023 | Dec 31, 2023 | -$51.06M | – |
| Q3 FY2023 | Sep 30, 2023 | -$49.54M | – |
| Q2 FY2023 | Jun 30, 2023 | -$42.47M | – |
| Q1 FY2023 | Mar 31, 2023 | -$39.84M | – |
See a number that looks wrong?